Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SOFIVA GENOMICS CoROCO:6615 +0.15%68 EBITDA Margin % is 5.53% as of Dec. 2025, which is 68% below its 10-year median of 17.54. GuruFocus rates ROCO:6615 with a GF Score™ of 68/100 and a GF Value™ of NT$30.94 (Fairly Valued). The stock has 3 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, SOFIVA GENOMICS Co ranks better than 55.67% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. SOFIVA GENOMICS Co's EBITDA for the
three
months ended in Dec. 2025 was NT$5.3 Mil. SOFIVA GENOMICS Co's Revenue for the
three
months ended in Dec. 2025 was NT$95.7 Mil. Therefore, SOFIVA GENOMICS Co's EBITDA margin for the quarter that ended in Dec. 2025 was 5.53%.
SOFIVA GENOMICS Co (ROCO:6615) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
SOFIVA GENOMICS Co EBITDA Margin % Related Terms
SOFIVA GENOMICS Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for SOFIVA GENOMICS Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6615 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, SOFIVA GENOMICS Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SOFIVA GENOMICS Co EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, SOFIVA GENOMICS Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where SOFIVA GENOMICS Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SOFIVA GENOMICS Co (ROCO:6615) has a EBITDA Margin % of 5.53% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SOFIVA GENOMICS Co and its competitors. This is 68% below median its historical median of 17.54. Over the past decade, SOFIVA GENOMICS Co's EBITDA Margin % has ranged from 8.85 to 23.17. According to the industry distribution chart, SOFIVA GENOMICS Co ranks #90 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 44.3%.
Is SOFIVA GENOMICS Co's EBITDA Margin % too high?
SOFIVA GENOMICS Co's current EBITDA Margin % of 5.53% is 68% below median its 10-year median of 17.54. Over the past 10 years, this metric has ranged from a low of 8.85 to a high of 23.17. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. SOFIVA GENOMICS Co's value of 5.53% is 10.6% above this industry median. Based on the distribution chart, SOFIVA GENOMICS Co ranks #90 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, SOFIVA GENOMICS Co has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does SOFIVA GENOMICS Co's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, SOFIVA GENOMICS Co ranks #90 out of 203 companies for EBITDA Margin %. This puts SOFIVA GENOMICS Co in the upper half of its industry. The industry median EBITDA Margin % is 5.00. SOFIVA GENOMICS Co's value of 5.53% is 10.6% above this benchmark. Historically, SOFIVA GENOMICS Co's own EBITDA Margin % has ranged from 8.85 to 23.17 over the past decade. While the company's 10-year median is 17.54 vs. the industry median of 5.00, SOFIVA GENOMICS Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SOFIVA GENOMICS Co's current EBITDA Margin % of 5.53% is 10.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SOFIVA GENOMICS Co and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SOFIVA GENOMICS Co's current EBITDA Margin % is 5.53%, which is 68% below median its own 10-year median of 17.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SOFIVA GENOMICS Co stock overvalued right now?
Based on GuruFocus' analysis, SOFIVA GENOMICS Co (ROCO:6615) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.94, compared to a current price of NT$34.05 — trading 10.1% above its estimated fair value. The current EBITDA Margin % is 5.53%, which is 68% below median its 10-year median of 17.54 and 10.6% above the Medical Diagnostics & Research industry median of 5.00. SOFIVA GENOMICS Co's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For SOFIVA GENOMICS Co (ROCO:6615), the current EBITDA Margin % is 5.53% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SOFIVA GENOMICS Co (ROCO:6615) Overvalued in 2026?
Based on GuruFocus' analysis, SOFIVA GENOMICS Co stock appears to be overvalued.
The current stock price of NT$34.05 is trading 10.1% above its estimated GF Value™ of NT$30.94.
GuruFocus considers SOFIVA GENOMICS Co to be Fairly Valued.
Key valuation signals for ROCO:6615:
EBITDA Margin %: 5.53% (68% below median its 10-year median of 17.54)
GF Value™: NT$30.94 vs. price of NT$34.05 (10.1% above fair value)
Industry Position: 10.6% above the Medical Diagnostics & Research median (#90 of 203)
No single metric tells the full story. See the ROCO:6615 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SOFIVA GENOMICS Co Ltd provides medical diagnostic services. The services offered by the company include Prenatal, Reproductive, Cancer, Precision Medicine, Newborn, and Rare Diseases. Its testing categories include Genetic, Biochemical, and Chromosome. The business items of Sofiva Group are pre-pregnancy, prenatal, and neonatal genetic testing and medical testing, and other service income. Geographically, it generates the vast majority of its revenue from Taiwan.
68GF Score
Get the complete analysis for ROCO:6615
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6615 has been successfully added to your 
